Is Intrexon Corporation Stock Now a Bargain?

According to data from S&P Global Market Intelligence , Intrexon Corporation (NYSE: XON), a synthetic biology company, saw its shares dip by 7.72% last month. The company's shares struggled after a disappointing second-quarter earnings release early in the month (Aug. 9).

Long story short: Intrexon's highly diversified biotech platform -- that has significant assets in agriculture, healthcare, and even biofuels -- has failed to make the company a profitable enterprise so far. In fact, Intrexon's last stated cash position of $157.2 million is only enough to last about two more years, given the company's average net loss of roughly $19 million per quarter.

Image source: Getty Images.

Source: Fool.com